Monoclonal antibody · Kills target cells, directed at CD45 (PTPRC) · developed by Actinium Pharmaceuticals
Iodine I 131 apamistamab is a radioimmunoconjugate in which the murine IgG1 anti-CD45 antibody BC8 carries the radioisotope iodine-131. The antibody binds CD45, a tyrosine phosphatase expressed on leukocytes including most leukemic cells, delivering radiation that destroys CD45-expressing cells. It is studied in acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02665065 | Phase 3 | Acute Myeloid Leukemia | Active not recruiting | ATNM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myelogenous LeukemiaAcute Myeloid LeukemiaAMLBone Marrow TransplantLeukemia, Acute MyelogenousLeukemia, Acute MyeloidLeukemia, Myeloid, AcuteMyelogenous Leukemia, AcuteMyeloid Leukemia, Acute
See ATNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ATNM catalysts and pipeline →